london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Management of central serous choroidopathy by half-dose photodynamic therapy with verteporfin

Session Details

Session Title: Quick Fire Free Paper 5

Session Date/Time: Sunday 14/09/2014 | 11:00-13:00

Paper Time: 11:20

Venue: Boulevard B

First Author: : J.Montero-Moreno SPAIN

Co Author(s): :    A.A. Merino-Iglesias   J.M. Ruiz-Moreno   I. Flores-Moreno   J. Ruiz-Medrano     

Abstract Details


To evaluate the efficacy and safety of photodynamic therapy (PDT) with half dose verteporfin in patients with chronic central serous chorioretinopathy (CCSC)


Single centre, retrospective, interventional study


Single centre, retrospective, interventional study


The clinical files and fluorescein angiogram and optical coherence tomography (OCT) imaging of patients with CCSC treated with half dose verteporfin PDT were revised


Thirty seven eyes from 35 patients (9 females and 26 males) were treated by half dose verteporfin PDT. The mean age was 53±12 years, and the mean follow-up was 17±10 months (range 3 to 34). Mean initial best corrected visual acuity (BCVA) was 70±12 ETDRS letters, and 75±15 letters by the end of the follow-up period. The initial diameter of the lesion was 2535 ±1046 µm and 698 ±982 µm by the end of the follow-up period. Eight eyes required further PDT treatment: 4 eyes with full-dose verteporfin PDT (that did not require further treatments); and 4 eyes with half-dose verteporfin PDT (two of them required a further re-treatment with full-dose verteporfin PDT).


Half-dose verteporfin PDT does not seem to provide better BCVA than reported in the literature for full-dose verteporfin PDT, and is associated with a higher rate of recurrences.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy